Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
SnapDx logo — company profile

SnapDx

Founded 2013 2 employees Seed Health Care

General Information

Company Name SnapDx
Founded Year 2013
Employees 2
Industries Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with SnapDx. To contact SnapDx, visit snapdx.co.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SnapDx compare?

A PDF of SnapDx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SnapDx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SnapDx

Sponsored by the health-tech accelerator StartUp Health, SnapDx is a pioneering startup founded in 2013 within the Health Care industry. Their innovation lies in developing a suite of visual apps that condense crucial medical guidelines and evidence-based research papers into visually interactive tools for health professionals. These tools are designed to be easily accessible during patient appointments, facilitating informed decision-making right at the point of care. A significant milestone for SnapDx was the Seed Round investment secured on 28 May 2014, which further bolstered their mission to revolutionize healthcare delivery.

Business keywords: mHealth, Clinical Decision Support, Medical Guidelines, Evidence-based Medicine, Clinical Research, Point of Care Tools, Health Professional Apps, Visual Interactive Tools, Healthcare Innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
StartUp Health
StartUp Health
28 May 2014

SnapDx Alternatives & Competitors

View All Alternatives
SnapDx vs
Point of Care Decision Support
Point of Care Decision Support United States

Improved Clinical Outcomes. Optimized Patient Care.

2 employees
Health Care
SnapDx vs
Evidencio
Evidencio The Netherlands

Medical decision support

12 employees
AI, Analytics
SnapDx vs
Clinical Pharmacogenetics Implementation Consortium
Clinical Pharmacogenetics Implementation Consortium United States

An international consortium interested in facilitating the use of pharmacogenetic tests for improvin...

Grant
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About SnapDx

SnapDx is developing a package of visual apps to incorporate key medical guidelines and evidence-based clinical research papers into compact, visual, interactive tools that health professionals can use right at the point of care during their patient appointments.
SnapDx was founded in 2013.
SnapDx operates in Health Care. Its work centres on mHealth, Clinical Decision Support, Medical Guidelines and Evidence-based Medicine.
SnapDx has approximately 2 employees.
SnapDx has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to SnapDx include Point of Care Decision Support , Evidencio, Clinical Pharmacogenetics Implementation Consortium, Evinance, MedicReS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SnapDx and Point of Care Decision Support are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SnapDx, https://bouncewatch.com/company/snapdx, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout